Compare Adaptive Biotechnologies Corp (ADPT) vs Apartment Investment and Management Co (AIV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Apartment Investment and Management Co — how do they compare? Adaptive Biotechnologies Corp trades at $20.12 (market cap $3.33B), while Apartment Investment and Management Co trades at $2.9 (market cap $422.94M). The key difference: Adaptive Biotechnologies Corp is far larger — about 7.9× Apartment Investment and Management Co's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Apartment Investment and Management Co nearer its low. Which is the better fit depends on your goals.
| ADPT | AIV | |
|---|---|---|
Market Cap | $3.33B | $422.94M |
Sector | Health | Real Estate |
52-Week High | $22.37 | $8.76 |
52-Week Low | $10.24 | $2.87 |
Enterprise Value | $3.19B | $669.06M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
AIV trades at $2.94, down 0.68% on the day, with a bearish technical signal from moving averages. The company reported a net income of $554.01M for 2025, driven by a significant tax benefit, though revenue declined to $138.49M. Analyst consensus is mixed with 1 Buy and 2 Hold ratings. A $1.30 per share liquidating distribution is scheduled for June 2026, reflecting corporate restructuring efforts.
Outlook is cautious due to volatile earnings history and declining revenue, but the high net income margin and planned distribution offer some investor appeal. Key risks include inconsistent operational performance and high leverage, while institutional sentiment remains neutral pending clearer growth catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Apartment Investment and Management Co
Apartment Investment & Management Co is a self-managed real estate investment trust. It is focused on property development, redevelopment and various other value-creating investment strategies, targeting the U.S multifamily market. Its operating segments are Development and Redevelopment
Read more on AIV →
